A king in the CASTLE? Optimum initial HIV protease inhibitor

The Lancet

Volumn 372, Issue 9639, 2008, Pages 604-606

  Torti, Carlo ^a   Frank, Ian ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LIPID; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; LIPID BLOOD LEVEL; MORBIDITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL; TREATMENT RESPONSE;

EID: 49649089061     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61253-2     Document Type: Note

References (18)

1. Molina J.M., Andrade-Villanueva J., Echevarria J., et al., for the CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48-week efficacy and safety results of the CASTLE study. Lancet 372 (2008) 646-655
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (Jan 29, 2008). www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed Aug 1, 2008).
3. Clumeck N., Pozniak A., Raffi F., and the EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management of HIV-infected adults. HIV Med 9 (2008) 65-71
4. Hammer S.M., Saag M.S., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 (2006) 827-843
5. Eron Jr. J., Yeni P., Gathe Jr. J., et al., for the KLEAN study team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368 (2006) 476-482
6. Walmsley S, Ruxrungtham K, Slim J, et al. The Gemini Study: saquinavir (SQV/r) vs lopinavir/r (LPV/r) plus emtricitabine/tenofovir (FTC/TDF) as initial therapy in HIV-1 infected patients. 11th European AIDS Conference/EACS, Madrid, Spain; Oct 24-27, 2007: PS1/4 (abstr).
7. Ortiz R., DeJesus E., Khanlou H., et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 22 (2008) 1389-1397
8. Gathe J, da Silva B, Loutfy M. Study M05-730 primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir tablets once daily vs twice daily, co-administered with tenofovir df + emitricitabine in ARV-naive HIV-1-infected subjects. 15th Conference on Retrovirus and Opportunistic Infections, Boston, MA, USA; Feb 3-6, 2008: 775 (abstr).
9. Rotger M., Taff P., Bleiber G., et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 192 (2005) 1381-1386
10. Rodríguez-Nóvoa S., Martín-Carbonero L., Barreiro P., et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21 (2007) 41-46
11. Malan N, Krantz E, David N et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naïve subjects, both with and without ritonavir: 48-week results from AI424-089. 13th Conference on Retrovirus and Opportunistic Infections, Denver, CO, USA; Feb 5-8, 2006: 107LB (abstr).
12. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
13. Riddler S.A., Haubrich R., DiRienzo G., et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358 (2008) 2095-2106
14. Markowitz M., Nguyen B.Y., Gotuzzo E., et al., for the Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46 (2007) 125-133
15. Saag M, Ive P, Heera J et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: Week 48 results of the MERIT study. 4th IAS Conference on HIV Pathogenesis and Treatment and Prevention, Sydney, Australia; July 22-25, 2007: WESS104 (abstr).
16. Pozniak A, Morales-Ramirez J, Mohapi L et al. 48-week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-naïve patients. 14th Conference on Retrovirus and Opportunistic Infections (CROI), Los Angeles, CA, USA; Feb 24-28, 2007: 144LB (abstr).
17. Walmsley S., Bernstein B., King M., et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346 (2002) 2039-2046
18. Gathe Jr. J.C., Ive P., Wood R., et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18 (2004) 1529-1537